Search Results - bryan+fleming

3 Results Sort By:
Tumor-pH–Triggered Doxorubicin Prodrug with On-Demand Shelf-Stable Precursor
This invention introduces a small-molecule doxorubicin prodrug that remains inert in blood and rapidly activates in the mildly acidic tumor microenvironment. Featuring a shelf-stable maleimide pre-prodrug that converts on demand to the ultra-acid-labile DMA form, it enables targeted chemotherapy with improved selectivity, scalable synthesis, and reduced...
Published: 10/10/2025   |   Inventor(s): Ming An, Lan Yao, Vladyslav Nazarenko
Keywords(s): Technologies
Category(s): Campus > Binghamton University
Multi-parametric Acoustic, Optical and Mechanical Imaging of Cervical Tissue Insufficiencies to Predict Preterm Birth
An enhanced image-guidance system that integrates ultrasound and photoacoustic into existing ablation systems to provide an enhanced image-guidance system for identification of cervical tissue changes during pregnancy and postpartum. Technology Summary Preterm delivery is a main cause of perinatal morbidity and mortality worldwide, which is associated...
Published: 10/1/2025   |   Inventor(s): Mohammad Mehrmohammadi, Sonia Hassan, Edgar Hernandez-Andrade, Yan Yan, Maryam Basij
Keywords(s): Driving Lifelong Health
Category(s): Technology Category > Women's Health, Technology Category > Medical Devices, Technology Category > Life Science, Technology Category > Imaging, Technology Category > Acoustics
High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers
Abstract: Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric...
Published: 5/14/2025   |   Inventor(s): Mitchell Ho, Nan Li, Bryan Fleming
Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotoxin, Medulloblastoma, Neuroblastoma, Recombinant Immunotoxin, Retinoblastoma, Rit
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing